Skip to main content

Table 4 Demographics and practice patterns of patients managed for osteoporosis/osteopenia (n = 100)

From: Endocrinology practice patterns of hypothyroidism and osteoporosis management in a U.S. tertiary academic medical center

Age (years)

 Mean ± SD

69.0 ± 11.5

Gender (n)

 Female

87

Race (n)

 Caucasian

74

 Asian

6

 Black

1

 Other

16

 Patient refused to answer

3

Visit type (n)

 New patient visit

38

 Established patient visit

62

Interval between current and next visits, months (mean ± SD)

4.43 ± 2.85

Patients with follow up within 6 months of current visit (n)

44

Indications for initial treatment (n)

 T-score less than −2.5

49

 Fragility fracture

17

 Osteopenia with positive FRAX® risk

6

Patients managed on different prior therapies (n)

54

 One prior therapy

29

 Two prior therapies

18

 Three prior therapies

7

Total duration of any prior therapiesa (months)

 Mean ± SD

73.4 ± 81.9

 Median (range)

48 (0.25–458)

Bone turnover marker(s) checked within 7 months of current visit (n)

68

  1. DXA Dual-energy X-ray absorptiometry
  2. FRAX® Fracture Risk Assessment Tool
  3. aTotal duration of therapy with any of the following, alendronate, zoledronic acid, denosumab, teriparatide, ibandronate, risedronate, and raloxifene (n=37; unknown in n=17)